{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:25:22Z","timestamp":1768994722862,"version":"3.49.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Am J Phys Med Rehabil"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The incidence of leptomeningeal disease (LMD) is believed to be increasing in part because of more effective chemotherapy treatments allowing cancer progression behind the blood-brain barrier. However, little has been published about the rehabilitation of this growing patient population. In this study, impairments and rehabilitation utilization by cytology-proven LMD patients receiving intrathecal chemotherapy at a cancer center are described. A total of 109 consecutive patients with pathology-confirmed LMD who received an intrathecal chemotherapy infusion from January 1, 2017, through October 31, 2017, were retrospectively reviewed. Of the 109 patients, 103 (95%) had impairments described in their medical record that could impact physical function, including 74 of 109 (68%) who had deconditioning or fatigue. Kaplan-Meier median survival from initial LMD diagnosis was 13.1 mos. The median number of hospital admissions and intrathecal chemotherapy administrations was both 8. Of the 109 patients, 43 (39%) had magnetic resonance imaging radiology interpreted LMD. Most LMD patients used rehabilitation services (95\/109, 87%) and most were able to forego post\u2013acute inpatient rehabilitation facilities (96\/109, 88%). Additional research and education for rehabilitation professionals about this increasingly common syndrome are needed.<\/jats:p>","DOI":"10.1097\/phm.0000000000001565","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T03:00:28Z","timestamp":1597374028000},"page":"100-104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Rehabilitation Utilization by Cancer Patients with Pathology-Confirmed Leptomeningeal Disease Receiving Intrathecal Chemotherapy"],"prefix":"10.1097","volume":"100","author":[{"given":"Jack B.","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy H.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana M.","family":"Molinares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward A.","family":"Pingenot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Bruera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250616","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11940-012-0182-9","article-title":"Leptomeningeal metastases","volume":"14","year":"2012","journal-title":"Curr Treat Options Neurol"},{"key":"bib3-20250616","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cncr.30911","article-title":"Leptomeningeal metastasis from systemic cancer: Review and update on management","volume":"124","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"bib4-20250616","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.breast.2015.11.005","article-title":"Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab","volume":"26","year":"2016","journal-title":"Breast"},{"key":"bib5-20250616","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1212\/WNL.29.10.1369","article-title":"Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology","volume":"29","year":"1979","journal-title":"Neurology"},{"key":"bib6-20250616","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/neuonc\/nou089","article-title":"Leptomeningeal metastasis: A response assessment in Neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials","volume":"16","year":"2014","journal-title":"Neuro Oncol"},{"key":"bib7-20250616","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nec.2010.08.006","article-title":"Leptomeningeal disease","volume":"22","year":"2011","journal-title":"Neurosurg Clin N Am"},{"issue":"suppl 4","key":"bib8-20250616","first-page":"S265","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","year":"2013","journal-title":"Surg Neurol Int"},{"issue":"5\u20136","key":"bib9-20250616","first-page":"237","article-title":"Pulsed erlotinib as sole treatment of leptomeningeal carcinomatosis: Can we avoid the use of intrathecal therapy?","volume":"5","year":"2014","journal-title":"World J Oncol"},{"key":"bib10-20250616","doi-asserted-by":"crossref","first-page":"73312","DOI":"10.18632\/oncotarget.20272","article-title":"Leptomeningeal disease: Current diagnostic and therapeutic strategies","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib11-20250616","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/pmrj.12207","article-title":"Retrospective analysis of acute rehabilitation outcomes of cancer inpatients with leptomeningeal disease","volume":"12","year":"2020","journal-title":"PM R"},{"key":"bib13-20250616","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3340\/jkns.2012.52.3.193","article-title":"Incidence and risk factors for leptomeningeal carcinomatosis in breast cancer patients with parenchymal brain metastases","volume":"52","year":"2012","journal-title":"J Korean Neurosurg Soc"},{"key":"bib14-20250616","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10549-011-1682-0","article-title":"Leptomeningeal metastases from breast cancer: Intrinsic subtypes may affect unique clinical manifestations","volume":"129","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"bib15-20250616","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3389\/fneur.2019.00839","article-title":"Leptomeningeal metastasis: The role of cerebrospinal fluid diagnostics","volume":"10","year":"2019","journal-title":"Front Neurol"},{"key":"bib16-20250616","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/PHM.0b013e3181ca2306","article-title":"Comparison of functional outcomes in low- and high-grade astrocytoma rehabilitation inpatients","volume":"89","year":"2010","journal-title":"Am J Phys Med Rehabil"}],"container-title":["American Journal of Physical Medicine &amp; Rehabilitation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PHM.0000000000001565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T21:17:01Z","timestamp":1750108621000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PHM.0000000000001565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/phm.0000000000001565","relation":{},"ISSN":["1537-7385","0894-9115"],"issn-type":[{"value":"1537-7385","type":"electronic"},{"value":"0894-9115","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}